Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival.

Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival.
复制标题

DOI:
10.1016/j.ccr.2014.04.005
复制
发表时间:
2014-06-16
期刊:
影响因子:
50.3
通讯作者:
Kalluri R
Kalluri R
中科院分区:
医学1区
文献类型:
--
作者:
Özdemir BC;Pentcheva-Hoang T;Carstens JL;Zheng X;Wu CC;Simpson TR;Laklai H;Sugimoto H;Kahlert C;Novitskiy SV;De Jesus-Acosta A;Sharma P;Heidari P;Mahmood U;Chin L;Moses HL;Weaver VM;Maitra A;Allison JP;LeBleu VS;Kalluri R

文献摘要

参考文献

被引文献

相似文献

胰腺导管腺癌(PDAC)与显著的纤维化和基质肌成纤维细胞有关,但其功能作用仍不清楚。构建了能够在胰腺癌中删除αSMA⁺肌成纤维细胞的转基因小鼠。在非侵袭性前体(胰腺上皮内瘤变,PanIN)阶段或PDAC阶段开始清除肌成纤维细胞,都会导致侵袭性、未分化的肿瘤,其缺氧情况加重、上皮 - 间质转化增强以及癌症干细胞增多,动物存活率降低。在PDAC患者中,肿瘤中肌成纤维细胞较少也与存活率降低相关。在肌成纤维细胞缺失的小鼠肿瘤中观察到免疫监视受抑制,CD4⁺Foxp3⁺调节性T细胞增加。虽然肌成纤维细胞缺失的肿瘤对吉西他滨没有反应,但抗CTLA4免疫疗法逆转了疾病加速并延长了动物的存活时间。这项研究强调了在针对PDAC中癌相关成纤维细胞时需谨慎。
Pancreatic ductal adenocarcinoma (PDAC) is associated with marked fibrosis and stromal myofibroblasts but their functional contribution remains unknown. Transgenic mice with ability to delete αSMA+ myofibroblasts in pancreatic cancer were generated. Depletion starting at either non-invasive precursor (PanIN) or the PDAC stage led to invasive, undifferentiated tumors with enhanced hypoxia, epithelial-to-mesenchymal transition and cancer stem cells, with diminished animal survival. In PDAC patients, lower myofibroblasts in their tumors also correlated with reduced survival. Suppressed immune surveillance with increased CD4+Foxp3+ Tregs was observed in myofibroblasts depleted mouse tumors. While myofibroblasts depleted tumors did not respond to Gemcitabine, anti-CTLA4 immunotherapy reversed disease acceleration and prolonged animal survival. This study underscores the need for caution in targeting carcinoma-associated fibroblasts in PDAC.
DOI: 10.1016/j.ccr.2011.11.024
发表时间: 2012-01-17
期刊: Cancer cell
影响因子: 50.3
作者:
Cooke VG;LeBleu VS;Keskin D;Khan Z;O'Connell JT;Teng Y;Duncan MB;Xie L;Maeda G;Vong S;Sugimoto H;Rocha RM;Damascena A;Brentani RR;Kalluri R
通讯作者: Kalluri R
DOI: 10.1158/1078-0432.ccr-03-0825
发表时间: 2004-11-01
影响因子: 11.5
作者:
Armstrong, T;Packham, G;Iredale, JP
通讯作者: Iredale, JP
DOI: 10.1016/j.ccr.2011.05.011
发表时间: 2011-06-14
期刊: Cancer cell
影响因子: 50.3
作者:
Guerra C;Collado M;Navas C;Schuhmacher AJ;Hernández-Porras I;Cañamero M;Rodriguez-Justo M;Serrano M;Barbacid M
通讯作者: Barbacid M
DOI: 10.1016/j.ccr.2005.04.023
发表时间: 2005-05-01
期刊: CANCER CELL
影响因子: 50.3
作者:
Hingorani, SR;Wang, LF;Tuveson, DA
通讯作者: Tuveson, DA
DOI: 10.1016/s1535-6108(03)00309-x
发表时间: 2003-12-01
期刊: CANCER CELL
影响因子: 50.3
作者:
Hingorani, SR;Petricoin, EF;Tuveson, DA
通讯作者: Tuveson, DA